The first stop for professional medicines advice

Cancers

12 results

Applied filters

Estimating dose equivalence from oral morphine to other opioids

1 April 2025Use our tool to obtain approximate dose equivalences of oral morphine to other oral opioids and help you calculate an estimated equivalent daily dose.

Switching between morphine and other opioids in palliative care

1 April 2025Switching between oral morphine and other oral opioids requires care and thoughtful application of a stepped process.

Hydrocortisone: informing intrathecal risk assessment

11 August 2022Hydrocortisone products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Methotrexate: informing intrathecal risk assessment

11 August 2022Methotrexate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Etoposide: informing intrathecal risk assessment

11 August 2022Etoposide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Rituximab: informing intrathecal risk assessment

11 August 2022Rituximab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Topotecan: informing intrathecal risk assessment

11 August 2022Topotecan products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Hydrocortisone acetate: informing intrathecal risk assessment

11 August 2022Hydrocortisone acetate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Cytarabine: informing intrathecal risk assessment

11 August 2022Cytarabine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Trastuzumab: informing intrathecal risk assessment

11 August 2022Trastuzumab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration